PBMs are middleman companies (often owned by insurance companies) with sole authority to negotiate drug prices and manage pharmacy access to therapeutics. Just three PBM companies control more than 80 ...
Debate over whether or not the Affordable Care Act, commonly known as Obamacare, worked and how President Trump's executive ...
President Donald Trump in a sometimes tense meeting Friday with the nation’s governors pressed them to enact the death ...
The Maryland House of Delegates has voted overwhelmingly to allow a state board to extend its mandate for lowering ...
The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...
An insurance trust utilized by 80 school districts in the state, mostly in Southern Illinois, has fallen $7 million in the ...
The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...
Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...
The DOJ backs Medicare price negotiations amidst a Novartis lawsuit, while President Trump vows to lower U.S. drug costs.
Exelixis reaffirmed its 2025 sales guidance of $2.15-$2.25 billion and reported sustained long-term efficacy for Cabometyx in ...
The big pharma sector is one that’s generally fallen out of favor for many investors over the past few decades, as large ...
The Food and Drug Administration said on Friday that the shortage of semaglutide injection products, such as Novo Nordisk's Wegovy, has been resolved. FDA's update led to renewed uncertainty for a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback